Masimo Corporation MASI received the FDA’s nod for its RD SET sensors to be used with Masimo Measure-through Motion and Low Perfusion SET pulse oximetry. The procedure is aimed at offering improved ...
IRVINE, Calif.-- (BUSINESS WIRE)-- Masimo (NASDAQ: MASI) announced today that RD SET ® sensors with Masimo Measure-through Motion and Low Perfusion™ SET ® pulse oximetry have received FDA clearance ...
IRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ: MASI) today announced the findings of an abstract presented last Saturday at the Society for Technology in Anesthesia 2022 Annual Meeting, which ...
The INSPIRE Trial Prospectively Assesses Pulse Oximeter Accuracy Using a Unique Real-world Study Design and in the Feasibility Study Showed No Clinically Significant Bias Between Patients with Light ...
About a week after the FDA convened its latest meeting to discuss strategies for reducing racial biases in widely available pulse oximetry technology, Masimo has released new study data suggesting ...
Masimo’s revolutionary SET® pulse oximetry has been shown in more than 100 independent and objective studies to outperform other pulse oximetry technologies – even before the revisions that achieved ...
In Feasibility Study for Large, Prospective, Real-World Trial, Masimo SET® Performed Accurately on Critically Ill Adult ICU Patients of All Skin Tones The INSPIRE Trial Prospectively Assesses Pulse ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results